Glucosamine and Chondroitin for Osteoarthritis: Do They Help Joint Pain?

Medically reviewed by Dr. Fowad Shahzad · Evidence current through 20 August 2026 · Next review 20 August 2027

Glucosamine and chondroitin are among the best-known supplements sold for knee pain and “ageing joints.” They are often advertised as cartilage builders, and combination products can be expensive. The science is much less certain than the marketing.

The most reliable conclusion is this: glucosamine and chondroitin are not proven to rebuild cartilage, cure osteoarthritis or reliably relieve knee or hip pain for most people. Some studies report small benefits, others report none, and major professional guidelines reach different conclusions. Product formulation and quality also vary, so the result from one pharmaceutical-grade preparation cannot automatically be transferred to every supplement on a pharmacy or online shelf.

For most adults, the foundations of osteoarthritis care—an accurate diagnosis, therapeutic exercise, muscle strengthening, weight management when relevant, education and appropriately selected pain treatment—deserve priority. A supplement should never delay assessment of a swollen, unstable or rapidly worsening joint.

The short answer

• Knee osteoarthritis: benefit is uncertain. The ACR/AF strongly recommends against glucosamine and chondroitin, alone or combined, for knee OA. AAOS says they may help mild-to-moderate knee OA but grades the recommendation Limited because the evidence is inconsistent.
• Hip osteoarthritis: evidence does not support glucosamine as an effective treatment.
• Hand osteoarthritis: chondroitin has a narrow, conditional recommendation from the ACR/AF, based largely on one trial; this is not evidence that every chondroitin product works.
• Combination products: taking glucosamine and chondroitin together has not consistently worked better than either alone or placebo.
• Cartilage protection: imaging studies conflict. These products should not be described as proven cartilage-regrowing or disease-modifying treatments.
• Safety: they are usually tolerated in trials, but “natural” does not mean interaction-free. Warfarin is the most important interaction concern, and people with diabetes, pregnancy, breastfeeding, severe allergy, multiple medicines or significant kidney/liver disease need an individual review.

What are glucosamine and chondroitin?

Glucosamine is used by the body in molecules that form part of cartilage and other connective tissues. Chondroitin is also a cartilage component and contributes to its ability to resist compression. This biological role makes the marketing story sound plausible—but swallowing a cartilage component does not prove that it reaches an arthritic joint, rebuilds damaged cartilage or changes the course of osteoarthritis.

Products are not interchangeable. Glucosamine may be supplied as glucosamine sulfate or glucosamine hydrochloride. Chondroitin is usually supplied as chondroitin sulfate. Some research involves prescription or pharmaceutical-grade preparations that may differ from ordinary retail supplements in formulation, purity, consistency and bioavailability. A study of a specific preparation cannot be treated as proof for every bottle bearing the same ingredient name.

Osteoarthritis is more than “wear and tear”

Osteoarthritis is a whole-joint disorder involving cartilage, bone, the joint lining, muscles and movement mechanics. It can cause activity-related pain, short-lived stiffness after rest, swelling and reduced function. The knees, hips and hands are commonly affected, and risk rises with age. Previous injury, genetics, muscle weakness and excess joint load can also matter.

Ageing adults should not assume that every painful joint is osteoarthritis. Gout, inflammatory arthritis, tendon or bursa problems, infection, a fracture, nerve pain and referred pain can mimic it. The pattern, examination and sometimes targeted testing determine the diagnosis; a supplement label cannot.

Why do the studies disagree?

Several factors make the evidence difficult to interpret:

1. Different formulations: sulfate and hydrochloride preparations are not identical, and prescription-grade products may not be equivalent to retail supplements.
2. Variable product quality: the stated amount, purity and absorption can differ between manufacturers.
3. Trial quality: some positive studies were small, older, at higher risk of bias or industry funded. Better-controlled public trials have often been less positive.
4. Large placebo and context effects: pain fluctuates, and expectations, attention and concurrent care can improve symptoms in both active-treatment and placebo groups.
5. Different joints and outcomes: a result for hand pain does not establish benefit for the knee or hip. A small change on an imaging measure does not necessarily mean a noticeable improvement in pain, walking or daily function.
6. Statistical versus clinical benefit: a pooled result can be statistically different from placebo yet still be too small for most patients to notice.

What does the evidence show for knee osteoarthritis?

The large GAIT trial did not show an overall benefit

The publicly funded Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) randomly assigned 1,583 adults with symptomatic knee osteoarthritis to glucosamine hydrochloride, chondroitin sulfate, their combination, celecoxib or placebo for 24 weeks. Overall, glucosamine, chondroitin and the combination were not significantly better than placebo for the main pain-response outcome. The active control, celecoxib, did separate from placebo, which helped show that the trial could detect an effective treatment.

An exploratory subgroup with moderate-to-severe pain appeared to respond to the combination. That subgroup was much smaller, the analysis was exploratory, and the finding was not the trial’s overall result. It is therefore a research signal, not proof that people with more severe pain should buy a combination supplement.

Patient-level analysis did not identify a reliable “responder” group

An individual-patient-data meta-analysis examined 1,663 participants from six glucosamine trials. In the five placebo-controlled trials independent of industry, glucosamine was no better than placebo for pain or function at three or 24 months. It also did not work better in predefined groups based on sex, body mass index, baseline pain, structural changes or inflammation.

There is no good evidence that female or male sex, higher body mass index, greater baseline pain, structural abnormalities or inflammation identifies a subgroup especially likely to benefit from glucosamine.

Longer-term pooled effects appear small and clinically doubtful

A 2021 network meta-analysis of 28 randomized trials involving 11,890 participants found small statistical signals for glucosamine and chondroitin on some symptom and structure outcomes. The authors judged those long-term benefits clinically questionable and concluded that none of the studied putative disease-modifying treatments had a clinically significant long-term benefit.

A 2024 systematic review continued to illustrate the disagreement: pooled chondroitin studies showed pain and function improvement, and pooled glucosamine-sulfate studies showed a joint-space signal, but the glucosamine–chondroitin combination did not significantly improve pain or function. Such findings do not remove the central problem—trials use non-equivalent products and vary in quality, bias and outcome measurement.

A 2015 Cochrane review of chondroitin found a small short-term pain signal in pooled studies, but most evidence was low quality and results became less convincing in larger, better-concealed or non-industry trials. This is another reason not to convert an average research signal into a promise for an individual patient.

Does the combination work better?

Not reliably. The idea that two cartilage-related ingredients must work better together is biologically appealing, but it is not a dependable clinical result. GAIT found no significant overall advantage for the combination. Several pooled analyses also fail to show that the combination consistently improves pain or function more than placebo.

In a two-year GAIT follow-up, no supplement group achieved a clinically important pain or function difference from placebo. This longer observation does not support continuing a product indefinitely in the hope that a delayed benefit will eventually appear.

Buying a combination product can also make interpretation harder. If symptoms improve or side effects occur, it is unclear which ingredient—if either—was responsible.

Can glucosamine or chondroitin regrow cartilage?

This claim is not established. Two large, two-year knee studies produced conflicting imaging results. In the Australian LEGS trial, the combination reduced joint-space narrowing, while glucosamine or chondroitin alone did not. In a US GAIT structural study, none of the active groups clearly differed from placebo for a predefined clinically important joint-space change; interpretation was also limited by less progression than expected.

Joint-space width is an indirect research measure, not a photograph of new cartilage. Even when a small structural difference is detected, it must also translate into meaningful pain, mobility or quality-of-life benefit. Current evidence does not justify advertising glucosamine or chondroitin as cartilage-regrowing, joint-rebuilding or disease-reversing therapy.

What about hip osteoarthritis?

Evidence is more discouraging for the hip. A randomized two-year trial in 222 primary-care patients found glucosamine sulfate no better than placebo for pain, function or joint-space narrowing. The ACR/AF guideline recommends against glucosamine for hip osteoarthritis, and NCCIH reaches the same evidence summary.

Deep hip or groin pain also has several possible causes. Persistent symptoms, loss of motion, night pain or difficulty bearing weight deserve assessment rather than repeated supplement trials.

What about hand osteoarthritis?

Hand osteoarthritis is the main exception in guideline wording. One single-centre six-month randomized trial of 162 people found between-group improvements favouring one highly purified chondroitin preparation: 8.7 mm on a 100-mm pain scale and 2.14 points on the 30-point FIHOA function scale. On this single-trial evidence, the ACR/AF conditionally recommends chondroitin for hand OA while recommending it against knee and hip OA; the result cannot be generalized to every product.

“Conditional” is important. It means the decision is preference-sensitive and the evidence is not strong enough to make it a routine choice for everyone. It does not validate every chondroitin brand, combination product or “joint formula.”

Why do major guidelines reach different conclusions?

The disagreement is not a reason to pick the most optimistic guideline. It is a reason to explain the quality, formulation and magnitude of evidence honestly.

Dr. Fowad’s evidence-based perspective

The evidence-grounded clinical interpretation is that glucosamine and chondroitin should not be presented as routine osteoarthritis treatment, cartilage rebuilding or guaranteed pain relief. Exercise-based rehabilitation, maintaining muscle, weight management when relevant, and a diagnosis-specific pain plan have stronger and more consistent support.

For a person with confirmed mild-to-moderate osteoarthritis who understands that benefit is uncertain, has no important interaction, can identify a credible product and still wishes to try it, a monitored, time-limited trial can be discussed as a preference-sensitive decision. That is a harm-reduction approach—not an endorsement and not proof of efficacy. Chondroitin for hand osteoarthritis is the one narrow area with conditional ACR/AF support.

The decision should be based on function, not vague impressions. A supplement that does not produce a clear, worthwhile improvement in a specific daily activity should not be continued indefinitely because the label promises future cartilage repair.

If someone still wants to try a supplement: use a stop rule

ACR/AF and NICE recommend against routine use, AAOS does not provide a proven retail-supplement regimen, and ESCEO’s formulation-specific prescription recommendations cannot be extrapolated to unverified retail products. No guideline establishes an ideal trial duration for a retail supplement. A pharmacist practice guideline suggests that adults who choose to try glucosamine or chondroitin despite uncertain efficacy should set a reassessment date and stop after a three-month trial if symptoms have not improved. That three-month interval is expert-consensus harm reduction—not proof of an optimal regimen.

Before starting, a clinician or pharmacist can help the person:

1. confirm that osteoarthritis is the likely cause of pain;
2. review warfarin, antiplatelet medicines, diabetes treatment and other prescriptions or supplements;
3. select one clearly identified product rather than changing several treatments at once;
4. record a baseline, such as pain during a specific activity and the ability to walk, climb stairs, open jars or complete another relevant task;
5. keep exercise and other established care stable enough to interpret the result; and
6. stop for adverse effects, a meaningful interaction, or no clear functional benefit at the agreed reassessment.

A small day-to-day fluctuation is not convincing evidence. “Meaningful” should be agreed in advance and should matter in real life—not merely be a one-point change noticed after reading the label.

Who might reasonably discuss a time-limited trial?

It may be reasonable to discuss—not automatically recommend—a trial when all of the following are true:

• osteoarthritis is reasonably established rather than self-diagnosed from any joint pain;
• symptoms are mild to moderate and there is no urgent red flag;
• evidence-based core care is already being used rather than replaced;
• the person understands that the likely benefit is small or absent and that cartilage regrowth is unproven;
• medicines and medical conditions have been reviewed for interactions;
• the product source, formulation, batch and expiry can be checked; and
• the person can afford a short trial without sacrificing higher-value care.

For hand osteoarthritis, the conditional evidence for chondroitin can be part of shared decision-making. For hip osteoarthritis, evidence does not support glucosamine.

Who should not self-start glucosamine or chondroitin?

Seek clinician or pharmacist advice first if any of the following applies:

• Warfarin or another coumarin anticoagulant: do not self-start either ingredient. Spontaneous pharmacovigilance reports—mostly involving glucosamine alone or glucosamine–chondroitin combinations—describe raised INR, bruising or bleeding. Contact the prescriber or anticoagulation service before starting, stopping or changing any product.
• Diabetes or prediabetes: NCCIH notes possible glucose increases in some people, although a 2.5-year randomized trial in overweight or obese middle-aged women found no significant effect on mean HbA1c or new diabetes. Evidence in people with established diabetes remains limited; plan glucose monitoring rather than assume no effect.
• Use of antiplatelet medicines, a bleeding disorder or an upcoming operation: disclose all supplements and follow the treating or surgical team’s instructions.
• Pregnancy or breastfeeding: safety data are insufficient.
• Shellfish allergy: food allergy is usually directed at shellfish proteins, and a 15-person challenge study found no reaction to one shrimp-derived product; that small, product-specific study cannot establish safety for every supplement. People with previous anaphylaxis should verify the source and excipients with an allergist or pharmacist before use.
• Significant kidney or liver disease, frailty or many medicines: the main issue is limited population-specific evidence and interaction burden, not proof that the supplement treats or protects these organs.
• A previous reaction to the product or its excipients: avoid re-exposure until reviewed.

Possible adverse effects and interactions

Trials generally report few serious problems, but possible effects include:

• nausea, heartburn, abdominal discomfort, diarrhoea or constipation;
• headache or skin reactions;
• an allergic reaction to the ingredient source or another component;
• altered glucose readings in some people; and
• increased anticoagulant effect with warfarin, potentially raising INR and bleeding risk.

Combination products may also contain methylsulfonylmethane, minerals, herbs or vitamins. Their safety cannot be inferred from glucosamine or chondroitin research. Read the complete ingredient list rather than the large words on the front label.

Product quality and regulatory checks in Pakistan

In Pakistan, DRAP classifies food supplements and nutritional products within alternative medicines and health products. DRAP states that these non-prescription products are not substitutes for medicines prescribed after proper diagnosis, and it enlists manufacturers, importers and products under the relevant rules.

Practical checks include:

• buy a sealed product from a traceable pharmacy or supplier;
• look for the manufacturer or importer, full ingredient form, batch or lot number, manufacturing and expiry dates, and storage instructions;
• ask a pharmacist to help verify the current manufacturer/importer and product status through official DRAP channels;
• do not treat an online marketplace listing, influencer claim or foreign label as evidence of quality or effectiveness;
• do not assume two products are equivalent simply because both say “glucosamine” or “chondroitin”; and
• do not interpret appearance on a provisional DRAP list as proof of current valid enlistment or clinical efficacy. DRAP’s own disclaimer says the provisional list is not evidence of validity.

No specific Pakistani brand was verified for this article, and no brand is endorsed. “DRAP approved” should not be written beside a named product unless its current, product-specific status has been checked from an authoritative record.

What should come before a supplement?

The ACR/AF and NICE place greater emphasis on:

• therapeutic exercise: strength, aerobic and mobility work adapted to the joint and the person;
• weight management when relevant: even modest weight change can reduce knee load, but it should be pursued without crash dieting or muscle loss;
• education and self-management: pacing, flare planning and realistic activity goals;
• appropriate supports: a cane, selected brace or occupational strategy when clinically indicated; and
• pain treatment chosen around individual risks: for example, topical anti-inflammatory treatment may be appropriate for some knee or hand OA, while oral anti-inflammatories require gastrointestinal, kidney, blood-pressure and cardiovascular risk review.

People with obesity or diabetes who avoid movement because of joint pain may need coordinated metabolic and musculoskeletal care. Medical weight management or a diabetes consultation and risk review does not replace assessment of the joint, and treating the joint does not replace management of those conditions.

When joint pain needs prompt assessment

Do not start another supplement and wait if there is:

• a hot, red or rapidly swollen joint, especially with fever;
• sudden severe pain, a recent injury, deformity or inability to bear weight;
• prolonged morning stiffness, several swollen joints, psoriasis or other signs of inflammatory arthritis;
• persistent night pain, unexplained weight loss or worsening pain without a clear mechanical pattern;
• new weakness, numbness or loss of bladder/bowel control; or
• calf swelling, chest pain or shortness of breath.

Some of these features require urgent or emergency care. They are not typical “ageing joint” problems to manage with an over-the-counter product.

Myths versus facts

Myth 1: “Glucosamine rebuilds worn cartilage.”

Fact: Cartilage biology provides a marketing rationale, not clinical proof. Structural trials conflict, and no major guideline describes retail glucosamine as proven cartilage-regrowing therapy.

Myth 2: “If one brand worked in a study, every brand works.”

Fact: Formulation, purity, manufacturing and bioavailability vary. Results from a prescription-grade preparation cannot be transferred automatically to an unverified retail product.

Myth 3: “The combination must be stronger.”

Fact: The combination has not consistently outperformed placebo or the individual ingredients for pain or function.

Myth 4: “Natural means safe with my medicines.”

Fact: Warfarin interaction is a clinically important concern, and combination formulas add more ingredients and uncertainty.

Myth 5: “Older adults and women should take it preventively.”

Fact: Osteoarthritis is more common with ageing and often affects women, but the patient-level analysis found no glucosamine benefit specific to sex, BMI, baseline pain severity, structural abnormalities or inflammation. It did not establish a preventive role in healthy joints.

Myth 6: “Less pain proves the joint has healed.”

Fact: Pain can fluctuate and improve for many reasons. Symptom change does not prove cartilage restoration or slowed disease.

Frequently asked questions

1. Do glucosamine and chondroitin work for knee osteoarthritis?

They may help some individuals, but trials and guidelines are inconsistent. The best low-bias evidence does not show a reliable, important benefit for most people, so routine use is not supported.

2. Is glucosamine sulfate better than glucosamine hydrochloride?

Some positive studies used specific prescription crystalline glucosamine-sulfate preparations, while GAIT used glucosamine hydrochloride and was negative overall. This may reflect formulation differences, study bias or both. It does not prove that any retail sulfate product will work.

3. Is chondroitin better than glucosamine?

There is no universal winner. Chondroitin has a narrow conditional recommendation for hand osteoarthritis, while knee and hip evidence remains inconsistent and ACR/AF recommends against routine use there.

4. Should I take both together?

Not simply because the label combines them. Combination therapy did not show a significant overall benefit in GAIT and has not consistently improved pain or function in pooled studies.

5. How long should I try it?

There is no guideline-proven ideal trial length. If an informed adult elects a trial after a medication and safety review, a predefined three-month reassessment is a pragmatic expert-consensus approach. Stop earlier for adverse effects and stop at reassessment if there is no clear, worthwhile functional benefit.

6. Can I take it if I have diabetes?

Do not assume it is glucose-neutral. NCCIH notes possible glucose increases in some people, while one 2.5-year trial in overweight or obese middle-aged women found no significant effect on mean HbA1c or new diabetes. Evidence in established diabetes remains limited, so discuss it with the clinician managing diabetes and agree on monitoring rather than changing diabetes medicines yourself.

7. Can I take it with warfarin?

Do not self-start either ingredient. NCCIH warns that glucosamine and chondroitin have been associated with increased bleeding risk in warfarin users; pharmacovigilance reports most often involve glucosamine-containing products. Ask the warfarin prescriber or anticoagulation service first.

8. Is it safe with shellfish allergy?

Shellfish allergy is usually directed at proteins rather than the shell source itself. One 15-person challenge study found no reaction to a specific shrimp-derived glucosamine product, but that small result cannot establish safety for every supplement. People with prior anaphylaxis should verify the product and excipients with an allergist or pharmacist.

9. Can it replace exercise, weight management or prescribed treatment?

No. Exercise and strengthening are core osteoarthritis treatments. Weight management can help selected people with knee or hip OA. Do not stop prescribed therapy or delay appropriate assessment for a supplement.

10. How do I choose a product in Pakistan?

No brand is endorsed here. Use a traceable pharmacy, check the manufacturer/importer, ingredient form, batch and expiry, and ask a pharmacist to verify current DRAP information. A provisional list or seller claim alone does not prove valid current status or effectiveness.

Bottom line

Glucosamine and chondroitin are popular, but popularity is not proof. For knee and hip osteoarthritis, reliable benefit is uncertain and often too small to be clinically meaningful; routine use is not supported by several major guidelines. Chondroitin for hand osteoarthritis is a limited, conditional exception. Neither ingredient is proven to regrow cartilage. See more evidence-based medical reviews for related educational guidance.

If someone still chooses a trial, the safest approach is informed and time limited: confirm the diagnosis, check interactions and product quality, define a functional goal, reassess by three months and stop if there is no meaningful benefit. Core osteoarthritis care should remain the priority.

Educational-purpose disclaimer: This article provides general education and is not a diagnosis, prescription, dosing instruction or substitute for an individual medical assessment. Do not start, stop or change a supplement, anticoagulant, diabetes medicine or pain treatment based on this page. Seek urgent care for a hot swollen joint with fever, major injury, inability to bear weight, chest pain, shortness of breath or another emergency symptom.

References and evidence record

All online sources were accessed on 20 August 2026. Publication/update dates below distinguish the source date from the access date.

1. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 ACR/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research. Published February 2020;72(2):149–162. doi:10.1002/acr.24131.
2. American College of Rheumatology. Osteoarthritis Clinical Practice Guideline landing page. Current page checked 20 August 2026; the listed final OA guideline remains the 2019 ACR/AF guideline.
3. American Academy of Orthopaedic Surgeons. Management of Osteoarthritis of the Knee (Non-Arthroplasty), Third Edition. Adopted 31 August 2021. Oral/dietary-supplement recommendation graded Limited because evidence is inconsistent.
4. National Center for Complementary and Integrative Health. Glucosamine and Chondroitin for Osteoarthritis: What You Need To Know. Last updated October 2023.
5. National Institute for Health and Care Excellence. Osteoarthritis in over 16s: diagnosis and management—Recommendations. NG226, published 19 October 2022.
6. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine. 2006;354(8):795–808. doi:10.1056/NEJMoa052771.
7. Runhaar J, Rozendaal RM, van Middelkoop M, et al. Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis. Annals of the Rheumatic Diseases. 2017;76(11):1862–1869. doi:10.1136/annrheumdis-2017-211149.
8. Yang W, Sun C, He SQ, et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis—a systematic review and network meta-analysis. Journal of General Internal Medicine. 2021;36(7):2085–2093. doi:10.1007/s11606-021-06755-z.
9. Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Annals of the Rheumatic Diseases. 2015;74(5):851–858. doi:10.1136/annrheumdis-2013-203954.
10. Gabay C, Medinger-Sadowski C, Gascon D, et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis & Rheumatism. 2011;63(11):3383–3391. doi:10.1002/art.30574.
11. Rabade A, Viswanatha GL, Nandakumar K, Kishore A. Evaluation of efficacy and safety of glucosamine sulfate, chondroitin sulfate, and their combination regimen in knee osteoarthritis. Inflammopharmacology. 2024;32(3):1759–1775. doi:10.1007/s10787-024-01460-9.
12. Knudsen JF, Sokol GH. Potential glucosamine–warfarin interaction resulting in increased INR. Pharmacotherapy. 2008;28(4):540–548. doi:10.1592/phco.28.4.540.
13. Kielly J, Davis EM, Marra C. Practice guidelines for pharmacists: The management of osteoarthritis. Canadian Pharmacists Journal. 2017;150(3):156–168. doi:10.1177/1715163517702168. The three-month stop rule is expert consensus, not trial-proven duration.
14. Drug Regulatory Authority of Pakistan. Alternative Medicines and Health Products—Product Categories. Last updated 27 September 2023.
15. Drug Regulatory Authority of Pakistan. Provisionally Enlisted Health & OTC Products. Last updated 17 June 2025; official disclaimer states that the provisional list is not evidence of enlistment validity.
16. Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database of Systematic Reviews. 2015;(1):CD005614. doi:10.1002/14651858.CD005614.pub2.
17. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin, their combination, celecoxib or placebo over two years. Annals of the Rheumatic Diseases. 2010;69(8):1459–1464. doi:10.1136/ard.2009.120469.
18. Sawitzke AD, Shi H, Finco MF, et al. Effect of glucosamine and/or chondroitin sulfate on progression of knee osteoarthritis. Arthritis & Rheumatism. 2008;58(10):3183–3191. doi:10.1002/art.23973.
19. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019;27(11):1578–1589. doi:10.1016/j.joca.2019.06.011.
20. Bruyère O, Honvo G, Veronese N, et al. An updated ESCEO algorithm recommendation for the management of knee osteoarthritis. Seminars in Arthritis and Rheumatism. 2019;49(3):337–350. doi:10.1016/j.semarthrit.2019.04.008.
21. Rozendaal RM, Koes BW, van Osch GJVM, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Annals of Internal Medicine. 2008;148(4):268–277. doi:10.7326/0003-4819-148-4-200802190-00005.
22. Gommans YMM, Runhaar J, Jacobs ML, Bierma-Zeinstra SMA. The effect of prolonged glucosamine usage on HbA1c levels and new-onset diabetes mellitus in overweight and obese middle-aged women. American Journal of Medicine. 2017;130(6):731–737.e6. doi:10.1016/j.amjmed.2016.11.038.
23. Villacis J, Rice TR, Bucci LR, Lehrer SB. Do shrimp-allergic individuals tolerate shrimp-derived glucosamine?. Clinical & Experimental Allergy. 2006;36(11):1457–1461. doi:10.1111/j.1365-2222.2006.02590.x.